How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Matt Blackman has 25+ years of experience as a financial writer and 11+ years of expertise as a research analyst; contributes to several publications. Fibonacci levels are horizontal lines on a ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recent insider activity at Recursion Pharmaceuticals included 2 transactions totaling $97,222.74. 1 tax payment and 1 sale were reported, with the sale representing $78,822.38 of the total.

At close: October 29 at 4:00:00 p.m. EDT ...